title: Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?
authors.forename: Fabián
authors.initials: F
authors.lastname: Pitoia
authors.forename: Osvaldo J
authors.initials: OJ
authors.lastname: Degrossi
authors.forename: Hugo
authors.initials: H
authors.lastname: Niepomniszcze
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011995:Recombination, Genetic; D013961:Thyroid Gland / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D013972:Thyrotropin / Q000008:administration & dosage*
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013972:Thyrotropin